Equities research analysts expect vTv Therapeutics Inc (NASDAQ:VTVT) to post earnings of ($0.11) per share for the current quarter, according to Zacks. Two analysts have made estimates for vTv Therapeutics’ earnings, with estimates ranging from ($0.16) to ($0.06). vTv Therapeutics posted earnings of ($0.06) per share in the same quarter last year, which would indicate a negative year over year growth rate of 83.3%. The business is expected to report its next earnings report on Thursday, November 14th.

According to Zacks, analysts expect that vTv Therapeutics will report full year earnings of ($0.53) per share for the current fiscal year. For the next year, analysts expect that the firm will report earnings of ($0.43) per share, with EPS estimates ranging from ($0.60) to ($0.25). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover vTv Therapeutics.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported ($0.09) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. The company had revenue of $1.83 million for the quarter, compared to the consensus estimate of $1.63 million.

A number of research analysts recently issued reports on VTVT shares. Northland Securities restated a “buy” rating and set a $8.00 price objective on shares of vTv Therapeutics in a research report on Thursday, August 1st. ValuEngine lowered vTv Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Zacks Investment Research cut vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of vTv Therapeutics in a report on Friday, August 16th.

In other vTv Therapeutics news, major shareholder Ronald O. Perelman bought 1,212,121 shares of the stock in a transaction that occurred on Tuesday, July 9th. The shares were purchased at an average cost of $1.65 per share, for a total transaction of $1,999,999.65. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Ronald O. Perelman bought 606,061 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were acquired at an average cost of $1.65 per share, for a total transaction of $1,000,000.65. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,442,424 shares of company stock valued at $7,265,500 over the last three months. 1.70% of the stock is currently owned by company insiders.

A hedge fund recently raised its stake in vTv Therapeutics stock. BlackRock Inc. grew its holdings in shares of vTv Therapeutics Inc (NASDAQ:VTVT) by 25.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 65,031 shares of the biotechnology company’s stock after purchasing an additional 13,305 shares during the period. BlackRock Inc. owned approximately 0.12% of vTv Therapeutics worth $93,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.64% of the company’s stock.

Shares of NASDAQ VTVT traded up $0.09 during mid-day trading on Friday, hitting $1.47. The company had a trading volume of 620,654 shares, compared to its average volume of 816,856. The stock has a market cap of $73.62 million, a price-to-earnings ratio of -2.13 and a beta of -3.64. vTv Therapeutics has a 12 month low of $0.68 and a 12 month high of $6.09. The firm’s 50 day simple moving average is $1.34 and its two-hundred day simple moving average is $1.56.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Featured Story: How can investors benefit from after-hours trading?

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.